TOKYO – Public backlash against the proposal and internal agreement to cut the price of anticancer drug Opdivo (nivolumab) by half continues. Japan's Ministry of Health, Labour and Welfare (MHLW) promised to work on regular biennial drug price review and said the emergency review of Opdivo price was an anomaly.